Jinxin Fertility Group Ltd. (HK:1951)
:1951
Want to see HK:1951 full AI Analyst Report?
Top Page
Jinxin Fertility Group Ltd.
(1951)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$2.50
▲(0.81% Upside)
Action:ReiteratedDate:04/27/26
The score is held down primarily by the 2025 financial deterioration—revenue decline and a sharp swing to a substantial net loss—despite a manageable leverage profile and positive operating cash flow. Technicals provide mild support with price above key moving averages and a positive MACD, but valuation is constrained by negative earnings (negative P/E) and no stated dividend yield.
Positive Factors
Specialized fertility services network
A focused network of fertility hospitals and clinics provides structural advantages: concentrated expertise, referral flows and operational scale in ART services. That business model sustains recurring, high-touch clinical demand and supports margin and customer retention over the medium term.
Negative Factors
2025 revenue decline and large net loss
A rare reversal to revenue decline and a very large net loss undermine earnings durability. Such a swing indicates structural pressure on demand, pricing or cost control, meaning recovery will require sustained revenue restoration or margin improvement over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized fertility services network
A focused network of fertility hospitals and clinics provides structural advantages: concentrated expertise, referral flows and operational scale in ART services. That business model sustains recurring, high-touch clinical demand and supports margin and customer retention over the medium term.
Read all positive factors
Jinxin Fertility Group Ltd. (1951) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.65B
Dividend Yield2.38%
Average Volume (3M)20.30M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-5.73%
EPS Growth-442.94%
CountryHK
Employees3,198
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.03
Shares Outstanding2,705,044,000
10 Day Avg. Volume21,878,483
30 Day Avg. Volume20,304,545
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.31Price Target Upside33.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.87B
Jinxin Fertility Group Ltd. Business Overview & Revenue Model
Company Description
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed ...
How the Company Makes Money
null...
Jinxin Fertility Group Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
63
Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.58B | 2.81B | 2.79B | 2.36B | 1.84B |
| Gross Profit | 818.44M | 1.10B | 1.18B | 913.13M | 771.48M |
| EBITDA | 538.60M | 645.06M | 682.02M | 476.21M | 494.08M |
| Net Income | -950.88M | 283.10M | 344.72M | 121.12M | 339.90M |
Balance Sheet | |||||
| Total Assets | 13.97B | 14.98B | 14.90B | 15.23B | 12.83B |
| Cash, Cash Equivalents and Short-Term Investments | 906.17M | 570.82M | 852.90M | 1.40B | 1.93B |
| Total Debt | 2.96B | 2.71B | 2.55B | 4.16B | 2.09B |
| Total Liabilities | 4.77B | 4.63B | 4.71B | 6.50B | 4.07B |
| Stockholders Equity | 9.15B | 10.27B | 10.09B | 8.64B | 8.55B |
Cash Flow | |||||
| Free Cash Flow | 218.33M | 489.30M | 510.92M | -417.65M | 263.62M |
| Operating Cash Flow | 475.94M | 629.20M | 684.48M | 541.74M | 343.45M |
| Investing Cash Flow | -154.86M | -293.27M | -375.04M | -1.38B | -1.57B |
| Financing Cash Flow | -6.66M | -458.29M | -950.45M | 460.14M | 955.05M |
Jinxin Fertility Group Ltd. Technical Analysis
Negative
2.48
Price Trends
2.40
Negative
2.43
Negative
2.65
Negative
Market Momentum
0.01
Negative
47.38
Neutral
20.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Negative. The current price of 2.48 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 2.40, and below the 200-day MA of 2.65, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 20.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1951.
Jinxin Fertility Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$7.02B | 7.50 | 15.36% | 2.61% | 7.60% | 17.41% | |
67 Neutral | HK$1.40B | 5.35 | 18.05% | 4.37% | -4.23% | 3.95% | |
66 Neutral | HK$5.27B | 18.12 | 33.08% | 1.97% | 16.70% | 38.98% | |
64 Neutral | HK$1.57B | 20.66 | 5.64% | 1.20% | 1.75% | ― | |
62 Neutral | HK$7.37B | 43.03 | 0.62% | ― | -9.81% | -72.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$6.65B | -6.17 | -10.66% | 2.38% | -5.73% | -442.94% |
* Healthcare Sector Average
HK:1951
Jinxin Fertility Group Ltd.
2.38
-0.52
-17.93%
HK:1526
Rici Healthcare Holdings Ltd.
0.88
-0.11
-11.11%
HK:2273
Gushengtang Holdings Limited
30.34
-0.79
-2.54%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
21.46
5.32
32.96%
HK:3309
C-MER Eye Care Holdings Limited
1.26
-0.40
-24.10%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
11.83
-2.13
-15.26%
Jinxin Fertility Group Ltd. Corporate Events
Jinxin Fertility Cancels 52.7 Million Repurchased Shares to Lift Per-Share Metrics
Apr 9, 2026
Jinxin Fertility Group Limited has cancelled 52,662,000 shares that it previously repurchased under general mandates granted in 2024 and 2025, reducing its total issued share capital from 2,757,706,043 to 2,705,044,043 shares. The board expects th...
Jinxin Fertility Swings to Heavy 2025 Loss but Declares First Dividend Since 2024
Mar 26, 2026
Jinxin Fertility Group reported 2025 revenue of about RMB2.65 billion, down 5.8% year on year, and swung to a net loss of roughly RMB983.9 million from a prior net profit, with loss attributable to shareholders at about RMB976.1 million. Despite w...
Jinxin Fertility Declares Final Cash Dividend for 2025
Mar 26, 2026
Jinxin Fertility Group Limited has declared a final ordinary cash dividend of HKD 0.0418 per share for the financial year ended 31 December 2025, with shareholder approval scheduled for 25 June 2026. The ex-dividend date is set for 29 June 2026, t...
Jinxin Fertility Unveils Aggressive Dividend and Buy-back Plan to Lift Shareholder Returns
Mar 26, 2026
Jinxin Fertility Group has proposed a final dividend of about RMB100 million for 2025, equal to roughly 20% of its non-IFRS adjusted EBITDA, despite industry headwinds and internal management transition. The payout, subject to shareholder approval...
Jinxin Fertility Boosts Capacity in Shenzhen and Sees U.S. IVF Demand Surge
Mar 4, 2026
Jinxin Fertility Group has launched trial operations at the new campus of Shenzhen Zhongshan Obstetrics and Gynecology Hospital, a centrally located facility four times larger than its original site, enabling expansion into VIP, specialty and inte...
Jinxin Fertility Sets March 26 Board Meeting to Approve 2025 Annual Results
Feb 23, 2026
Jinxin Fertility Group Limited has scheduled a board meeting for March 26, 2026, to review and approve the group’s annual results for the financial year ended December 31, 2025. The move signals the company’s upcoming earnings disclosu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.